Neogap and Simsen Diagnostics enter collaboration to improve personalised cancer diagnostics
The biotechnology company Neogap and the cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalised cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap's phase I/II clinical trial. The goal is to develop more precise and effective diagnostic tools for cancer.Neogap Therapeutics has previously announced its plans to initiate a phase I/II clinical trial of its personalised cell therapy for the treatment of patients with disseminated colorectal cancer.
Neogap's pTTL (personalized Trained